Introduction {#s1}
============

The physiological relevance of cerebral insulin action remains incompletely understood ([@B1],[@B2]). The insulin receptor is expressed throughout the brain ([@B3]), and genetic manipulation of insulin receptors and components of the insulin signaling pathway has resulted in phenotypes of altered body weight ([@B4]), fertility ([@B4]) and counterregulatory response to hypoglycemia ([@B5],[@B6]). We have previously shown that hypothalamic insulin receptors are implicated in the regulation of hepatic glucose production (HGP) and energy expenditure (EE) ([@B7]). Insulin signaling through insulin receptor substrate 2 in the brain ([@B8]) leads to the activation of phosphatidylinositol triphosphate kinase ([@B9]), where convergence with the leptin signaling pathway occurs. A common effector of both insulin and leptin signaling is forkhead box O1 transcription factor (FoxO1) ([@B10],[@B11]).

Various neuron type--specific manipulations of FoxO1 have resulted in clearly defined roles of FoxO1 in the actions of insulin and leptin. Both FoxO1 and the leptin-responsive transcription factor signal transducer and activator of transcription 3 regulate key promoters in orexigenic agouti-related peptide (AgRP) and anorexigenic proopiomelanocortin (POMC) neurons ([@B12]), and delivering constitutively active FoxO1 to the hypothalamus increases food intake and body weight ([@B13],[@B14]). Within AgRP neurons, FoxO1 affects both eating behavior and the ability of insulin to regulate HGP, and indirect evidence implicates the orphan G-protein--coupled receptor Gpr17 as a FoxO1 target responsible for its orexigenic effects ([@B15]), in addition to neuropeptide AgRP ([@B12]) and neuropeptide Y (Npy) ([@B13]). Within POMC neurons, FoxO1 enhances food intake by decreasing the processing of POMC-derived anorexigenic peptides through inhibition of carboxypeptidase E expression ([@B16]). Outside the arcuate nucleus, FoxO1 decreases EE and increases transcription of steroidogenic factor 1 in the ventral medial nucleus of the hypothalamus (VMH) ([@B17]). From these data, the overarching function of FoxO1 in the hypothalamus appears to be anabolic.

While these data provide a necessary anatomic-functional map of FoxO1 actions, they do not address the broader question of the overall role of FoxO1 in vivo. To fill this gap in knowledge, we sought to determine whether combined inactivation of FoxO1 in multiple neuronal types, as would be expected to occur in response to feeding, would enhance the anorexigenic effects of FoxO1 removal from individual cell populations. To accomplish this goal, we used mice expressing Cre recombinase throughout a majority of hypothalamic neurons by way of the *Nkx2.1* promoter. This transgenic line allows the expression of Cre recombinase within multiple cellular subtypes within the hypothalamus ([@B18]). Nkx2.1-Cre is expressed as early as embryonic day 10.5 ([@B19],[@B20]) and is expressed in arcuate Npy and POMC neurons ([@B21]). We report here that mice with a genetic knockout of FoxO1 in the hypothalamus display mild decreases in body weight early in life that normalize as compensatory mechanisms exert their effects with age.

Research Design and Methods {#s2}
===========================

Maintenance and Care of Mouse Colony {#s3}
------------------------------------

Mice were housed in a specific pathogen--free animal facility, fed Picolab diet 5053 (Purina, Richmond, IN) or D124921 60% high-fat diet (HFD) (Research Diets, New Brunswick, NJ), and kept under a 12-h light/dark cycle. Nkx2.1-Cre mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and backcrossed with mice having a C57BL/6J background for eight generations. Mice with loxP-flanked FoxO1 alleles have been previously described ([@B22]). All procedures were approved by the institutional animal care and utilization committee at Columbia University.

Real-Time PCR {#s4}
-------------

Total RNA was isolated using the PerfectPure RNA Tissue Kit (5Prime, Gaithersburg, MD), and cDNA was made using qScript (Quanta Biosciences, Gaithersburg, MD), both according to the manufacturer's instructions. Real-time quantitative PCR (qPCR) was performed using GoTaq qPCR master mix (Promega, Madison, WI) on a C1000 Thermal Cycler with a CFX96 Real Time PCR Detection System (Bio-Rad, Hercules, CA). Pooled samples were used to generate serial 1:4 dilutions for standard curves. Primer sequences are available upon request.

Tissue RT-PCR {#s5}
-------------

Total RNA was isolated using the PerfectPure RNA tissue kit (5Prime), and complimentary DNA was made using qScript (Quanta Biosciences)---both according to the manufacturers' instructions as described above. cDNA was added to the FoxO1 primers previously described ([@B22]) and was mixed with KAPA 2 × 2G Fast ReadyMix with dye (Kapa Biosystems, Woburn, MA). PCR was performed with the following program: 95°C for 4 min (1 cycle), 94°C for 30 s, 58°C for 30 s, 72°C for 45 s (38 cycles), 72°C for 10 min (1 cycle), and 4°C to finish. Electrophoresis was performed on a 2% agarose gel, and ethidium bromide staining was visualized by ultraviolet light.

Metabolic Cages and Body Composition {#s6}
------------------------------------

Mice were acclimated for 2 days in cages, and indirect calorimetry, activity, and food intake were measured during the light and dark cycles using the LabMaster Platform (TSE Systems, Chesterfield, MO) as previously described ([@B15]). For fasting-refeeding experiments, food was removed at 1700 h and replaced the next day at 0800 h.

Serum Analytes {#s7}
--------------

Blood was removed from the tail of mice that were fasted overnight, ad libitum fed, or fasted overnight followed by 4-h refeeding. Blood was collected via heparinized capillary tubes and centrifuged to isolate serum. Serum was analyzed using mouse insulin ELISA (Mercodia, Uppsala, Sweden); leptin ELISA (Millipore, Billerica, MA); active ghrelin ELISA (Millipore, St. Charles, MO); and kits for cholesterol E (Wako, Richmond, VA), Infinity triglycerides (TGs) (Thermo Scientific, Middletown, VA), and nonesterified fatty acid (NEFA) (Wako) according to the manufacturer's instructions.

Neuropeptides {#s8}
-------------

AgRP was measured by radioimmunoassay (RIA) using an antibody (provided by Dr. Gregory Barsh, Stanford University School of Medicine, Stanford, CA) directed at the COOH-terminal end of the molecule. The RIA was performed as previously described using synthetic human AgRP~83--132~ for the standard and iodinated tracers (Phoenix Pharmaceuticals, Burlingame, CA) ([@B23]). Npy was measured with an RIA kit (Phoenix Pharmaceuticals), and α-melanocyte--stimulating hormone (α-MSH) and β-endorphin protein (β-Ep) were measured as previously described ([@B16],[@B23]).

Immunohistochemistry and Microscopy {#s9}
-----------------------------------

Liver tissue was fixed in formalin overnight, transferred to 70% ethanol, and paraffin embedded. Sections were cut to 5 μm, and hematoxylin-eosin (H-E) staining was performed. Brightfield images were taken using a Nikon eclipse E400 microscope. For brain tissue, mice were perfused with PBS followed by 4% paraformaldehyde. Brains were removed and fixed in 4% paraformaldehyde overnight, followed by placement into 30% sucrose in PBS solution for 2 days. Free-floating sections were cut to 20 μm using a cryostat and mounted onto glass slides using Prolong Gold antifade reagent (Life Technologies, Grand Island, NY). Fluorescent images were obtained using either a Nikon Eclipse 80i microscope with images merged using Adobe Photoshop CS4 or a Zeiss LSM710 Confocal microscope with images merged using Zen 2011 software (Carl Zeiss MicroImaging, Thornwood, NY). Antibodies used were for FoxO1 (C29H4; Cell Signaling Technology, Danvers, MA), Nkx2.1/Ttf1 (rabbit ab76013, mouse ab140245; Abcam, Cambridge, MA), and Npy (ab30914; Abcam).

Body Temperature and Cold Exposure {#s10}
----------------------------------

Following overnight fasting at room temperature, body temperature was measured rectally using Precision Thermometer 4600 (YSI, Yellow Springs, OH). Mice were then placed at 4°C for 4 h, and temperature was remeasured while mice remained under acute cold exposure.

Liver TGs and Cholesterol {#s11}
-------------------------

Liver tissue was homogenized and TGs and cholesterol were isolated via extraction as previously reported ([@B24]). TGs were measured with Infinity Triglycerides reagent (Thermo Scientific), and cholesterol was measured with a cholesterol E kit (Wako).

Statistics {#s12}
----------

Experiments were quantitated by two-tailed Student *t* test or one-way ANOVA using Prism software (GraphPad Software, La Jolla, CA). Results are presented as means ± SEM, and statistical significance is defined as *P* \< 0.05.

Results {#s13}
=======

Generation of Mice Lacking FoxO1 in Nkx2.1 Neurons {#s14}
--------------------------------------------------

To probe the function of FoxO1 in the hypothalamus, we generated a conditional null allele by crossing *Foxo1^lox/lox^* with Nkx2.1-Cre mice. To assess recombination, we introduced a *Rosa26-Tomato* reporter allele and surveyed fluorescence patterns in the central nervous system. We observed diffuse fluorescence in the hypothalamus ([Supplementary Fig. 1*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0651/-/DC1)) ([@B18]), as well as in the hippocampus and cortex ([Supplementary Fig. 1*B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0651/-/DC1)), as reported (<http://cre.jax.org/Nkx2/Nkx2.html>) ([@B18]). Nkx2.1-Cre was expressed in tanycytes lining the third ventricle but not in glial cells ([Supplementary Fig. 1*C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0651/-/DC1)). Deletion of FoxO1 did not result in compensatory increases in mRNA encoding other isoforms, *Foxo3a* and *Foxo4* ([Supplementary Fig. 2*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0651/-/DC1)). Double immunofluorescence revealed colocalization of FoxO1 and Nkx2.1 protein in many neurons, as well as neurons independently labeled with either FoxO1 or Nkx2.1 ([Supplementary Fig. 2*B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0651/-/DC1)). Expression of the Nkx2.1-Cre recombinase decreased the levels of Foxo1 in Nkx2.1-labeled cells. Reverse transcription of RNA isolated from peripheral tissues followed by PCR amplification of the resulting cDNA revealed Nkx2.1-Cre expression in hypothalamus and lung but not in other organs ([Supplementary Fig. 2*D*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0651/-/DC1)).

Characterization of Foxo1KO^Nkx2.1^ Mice {#s15}
----------------------------------------

Starting as early as 6 weeks of life, Foxo1KO^Nkx2.1^ mice of both sexes weighed less than wild-type (WT) counterparts ([Fig. 1*A* and *B*](#F1){ref-type="fig"}). In males, body weights of Foxo1KO^Nkx2.1^ mice caught up with WT mice by 5 months of age. The convergence of body weights in male Foxo1KO^Nkx2.1^ mice at 5 months of age could be due to compensatory mechanisms, such as decreasing numbers of POMC neurons, as we have reported in a different model of FoxO1 ablation ([@B25]). In males, the transient decrease of body weight is due to a proportional as well as an absolute decrease of fat mass, while the proportion of lean mass is higher as measured at 3 months of age ([Fig. 1*C*, *D*, *F*, and *G*](#F1){ref-type="fig"}). Fluid mass was not affected in Foxo1KO^Nkx2.1^ mice ([Fig. 1*E* and *H*](#F1){ref-type="fig"}). Female Foxo1KO^Nkx2.1^ mice also showed a decrease of fat mass, though not a significant decrease, and a larger decrease of lean mass, both of which were proportional to the decreased body weight ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0651/-/DC1)).

![Growth curves. Body weights of 4- to 20-week-old male (*A*) and female (*B*) mice (*n* \> 10 for each genotype). Total fat mass (*C*), lean mass (*D*), and fluid mass (*E*) in 3-month-old male mice as measured by magnetic resonance imaging (*n* ≥ 18). Fat mass (*F*), lean mass (*G*), and fluid mass (*H*) shown as the percentage of total body weight. All results represent means ± SEM. \**P* \< 0.05. KO, knockout.](1572fig1){#F1}

We did not observe changes in metabolic parameters. Two-month-old Foxo1KO^Nkx2.1^ mice have normal fasting and ad libitum--fed glucose levels ([Table 1](#T1){ref-type="table"}). There are no differences in serum insulin, TG, or free fatty acid (FFA) levels between WT and Foxo1KO^Nkx2.1^ mice. Fasted serum levels of these metabolites are also similar in 7-month-old mice ([Supplementary Fig. 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0651/-/DC1)).

###### 

Metabolic parameters

![](1572tbl1)

EE Studies {#s16}
----------

We postulated that the decreased body weight was at least partly due to increased EE in Foxo1KO^Nkx2.1^ mice because altered FoxO1 expression in steroidogenic factor 1 neurons in the VMH leads to increases in EE ([@B17]). We analyzed Foxo1KO^Nkx2.1^ mice using metabolic cages for indirect calorimetry and food intake measurements during the period (at 4 months of age) in which male Foxo1KO^Nkx2.1^ mice remain lighter in this cohort (body weight 23.52 ± 1.47 vs. 25.29 ± 0.96 g) and lean (body fat 7.8 ± 0.5 vs. 9.1 ± 0.2%). However, measurements of respiratory exchanges demonstrated similar levels of *V*[co]{.smallcaps}~2~ and *V*[o]{.smallcaps}~2~ between WT and Foxo1KO^Nkx2.1^ mice in either the dark or the light phases of the light cycle ([Fig. 2*A* and *B*](#F2){ref-type="fig"}). The 12-h respiratory exchange rates and locomotor activity levels were also similar ([Fig. 2*C* and *D*](#F2){ref-type="fig"}). To study metabolic flexibility in substrate use, we fasted mice overnight and then refed them. Neither *V*[co]{.smallcaps}~2~ nor *V*[o]{.smallcaps}~2~ was different between WT and Foxo1KO^Nkx2.1^ mice in this experiment ([Fig. 2*E* and *F*](#F2){ref-type="fig"}). Both groups of animals dropped their respiratory quotient similarly following fasting and rebounded equally upon refeeding ([Fig. 2*G*](#F2){ref-type="fig"}). Female Foxo1KO^Nkx2.1^ mice exhibited the same substrate use as males and showed no differences from WT controls ([Supplementary Fig. 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0651/-/DC1)).

![Energy balance in 4-month-old male mice. *A*--*D*: Ad libitum--fed animals. *V*[co]{.smallcaps}~2~ (*A*) and *V*[o]{.smallcaps}~2~ (*B*) during a representative 12-h dark/light cycle. Respiratory exchange ratio (*C*) and locomotor activity (*D*) during a representative 12-h dark/light cycle. *E*--*G*: Fasting/refeeding experiments. *V*[co]{.smallcaps}~2~ (*E*), *V*[o]{.smallcaps}~2~ (*F*), and respiratory exchange ratio (*G*) before and after fasting and following refeeding in 26-min increments. Data show means ± SEM. hr, hour; KO, knockout.](1572fig2){#F2}

Food Intake Studies {#s17}
-------------------

With no discernible differences in EE, we ascertained the role of food intake in the leanness of Foxo1KO^Nkx2.1^ mice. Male mice exhibited normal absolute and body weight--normalized food intake ([Fig. 3*A* and *B*](#F3){ref-type="fig"}). Female Foxo1KO^Nkx2.1^ mice, on the other hand, exhibited decreased overall food intake but normal intake proportional to their decreased size ([Fig. 3*C* and *D*](#F3){ref-type="fig"}). In both males and females, rebound food intake after an overnight fast mirrored ad libitum food intake, with no difference in males ([Fig. 3*E* and *F*](#F3){ref-type="fig"}) but weight-proportional decreases in females ([Fig. 3*G* and *H*](#F3){ref-type="fig"}).

![Assessment of food intake. *A*: Total food intake of 4-month-old male mice (*n* ≥ 7) during the 12-h dark/light cycle and over 24 h. *B*: Food intake normalized by body weight during 12-h dark/light cycle and over 24 h. *C*: Total food intake of 4-month-old female mice during the 12-h dark/light cycle and over 24 h. *D*: Food intake normalized by female body weight during 12-h dark/light cycle and over 24 h. *E*: Total food intake in males over 24 h following overnight fast. *F*: Food intake in males after overnight fast normalized by body weight. *G*: Total food intake in females over 24 h following overnight fast. *H*: Food intake in females after overnight fast normalized by body weight. Data show means ± SEM. \**P* \< 0.05. BW, body weight; KO, knockout.](1572fig3){#F3}

FoxO1 regulates the transcription of anorexigenic and orexigenic genes, as well as enzymes that process the neuropeptide products of those genes ([@B12],[@B13],[@B16]). While anorexigenic genes *Agrp* and *Npy* significantly decreased in male Foxo1KO^Nkx2.1^ mice, there were no differences in *POMC* levels ([Fig. 4*A*](#F4){ref-type="fig"}). Since the decreases in AgRP and Npy were ∼50%, we postulated that Nkx2.1-Cre may not target all AgRP/Npy neurons, consistent with Nkx2.1-Cre--driven green fluorescent protein (GFP) reporter colocalization studies ([@B21]). However, previous use of the Nkx2.1-Cre revealed nearly complete targeting of leptin-sensitive neurons, as visualized by reductions in phosphorylated signal transducer and activator of transcription 3 upon deletion of the leptin receptor ([@B18]). To quantify the proportion of AgRP/Npy neurons targeted by the Nkx2.1-Cre, we introduced the Npy-GFP reporter into the WT and Foxo1KO^Nkx2.1^ mice. We found virtually no Npy-GFP in the hypothalamus of Foxo1KO^Nkx2.1^ mice ([Fig. 4*B*](#F4){ref-type="fig"}), though Npy-GFP was observed in other parts of the brain such as the cortex ([Supplementary Fig. 6*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0651/-/DC1)). Of note, the Nkx2.1-Cre (as visualized by inclusion of the Tomato reporter) did not colocalize with Npy-GFP outside of the hypothalamus. The Tomato reporter under Nkx2.1-Cre served as evidence of Cre-driven recombination within the hypothalamus, and Npy-GFP in nonhypothalamic areas provided evidence of proper genetic cross and sufficient GFP fluorescence for detection.

![Hypothalamic neuropeptides. *A*: qPCR measurement of hypothalamic neuropeptide mRNA in overnight-fasted, 5-month-old male WT and Foxo1KO^Nkx2.1^ mice (*n* ≥ 7). *B*: Npy-GFP expression in arcuate nucleus of overnight fasted mice. Representative image shown. *C*: Protein levels of α-MSH, β-Ep, AgRP, and Npy in hypothalamus of overnight fasted, 5-month-old male WT and Foxo1KO^Nkx2.1^ mice (*n* ≥ 7). *D*: Serum levels of active ghrelin following overnight fast or overnight fast followed by 4 h refeeding (*n* ≥ 5). Results are presented as means ± SEM. \**P* \< 0.05. Hprt, hypoxanthine guanine phosphoribosyl transferase; AU, arbitrary units; KO, knockout.](1572fig4){#F4}

With the dramatic decrease in Npy-GFP expression in Foxo1KO^Nkx2.1^ mice, we hypothesized that, whereas *Agrp/Npy* transcripts appeared decreased but still present in the hypothalamus, the protein was reduced or unstable. We measured levels of AgRP and Npy neuropeptides and found significant decreases that correlated with transcript levels ([Fig. 4*C*](#F4){ref-type="fig"}). Levels of POMC-produced neuropeptides α-MSH and β-Ep were not altered in the Foxo1KO^Nkx2.1^ mice, which is consistent with normal *POMC* transcript levels. The amount of Npy protein present in the arcuate nucleus and paraventricular nucleus revealed persistent levels in Foxo1KO^Nkx2.1^ mice that did not match the difference in the Npy-GFP reporter ([Supplementary Fig. 6*B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0651/-/DC1)). We considered that Npy-GFP reporter activity may be compromised by the loss of a cofactor that binds to the Npy promoter fragment affected by insertion of the transgene; thus, we looked at alternate signaling pathways that may interact with FoxO1 on the Npy promoter. The ghrelin receptor is located in hypothalamic AgRP/Npy neurons and elicits a similar orexigenic effect upon stimulation by ghrelin ([@B26]). But we did not observe differences in serum levels of active ghrelin after either fasting or refeeding ([Fig. 4*D*](#F4){ref-type="fig"}), and we also did not find differences in ghrelin receptor transcript or protein levels (data not shown).

Foxo1KO^Nkx2.1^ Mice Are Not Protected From Diet-Induced Obesity {#s18}
----------------------------------------------------------------

Given the transient decrease of body weight in Foxo1KO^Nkx2.1^ mice on a chow diet, we used a diet containing 60% fat (HFD) to determine whether hypothalamic loss of FoxO1 protects from diet-induced obesity. Male Foxo1KO^Nkx2.1^ mice weighed less than WT mice at the start of the experiment, but the difference in body weight normalized on an HFD ([Fig. 5*A*](#F5){ref-type="fig"}). HFD also normalized body composition differences between WT and Foxo1KO^Nkx2.1^ mice ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0651/-/DC1)), abolishing differences in fat mass and lean mass content, as seen in younger mice. Foxo1KO^Nkx2.1^ mice were slightly shorter than WT mice at 5 months of age, and the difference reached statistical significance by 10 months ([Fig. 5*H* and *I*](#F5){ref-type="fig"}). An HFD increased the body length of mice of both genotypes to the same extent.

![Metabolic effects of HFD. Body weight (*A*), whole-blood glucose (*B*), insulin (*C*), leptin (*D*), cholesterol (*E*), TGs (*F*), and FFAs (*G*) measured in serum of overnight-fasted male mice following a 10-week HFD (*n* = 5--8). *H*: Ano-nasal body length of males following HFD. *I*: Ano-nasal body length of 10-month-old male mice on regular chow diet (*n* = 5--8). Results are presented as means ± SEM. \**P* \< 0.05. HF, high fat; KO, knockout; mEq, milliequivalent; RD, regular diet.](1572fig5){#F5}

Foxo1KO^Nkx2.1^ mice exhibited a slight but not significant decrease in fasting glucose levels on regular chow and HFD ([Fig. 5*B*](#F5){ref-type="fig"}). We saw no differences in fasting serum insulin levels ([Fig. 5*C*](#F5){ref-type="fig"}). While HFD produced a large increase in fasting leptin levels compared with regular diet, it resulted in no differences between Foxo1KO^Nkx2.1^ and WT mice ([Fig. 5*D*](#F5){ref-type="fig"}). Serum cholesterol levels followed a similar pattern, being raised by HFD, but not differently so in the two genotypes ([Fig. 5*E*](#F5){ref-type="fig"}). In contrast, we saw a slight elevation in serum levels of TGs in HFD-fed Foxo1KO^Nkx2.1^ mice compared with WT mice ([Fig. 5*F*](#F5){ref-type="fig"}). Serum levels of FFAs were slightly decreased on HFD, but the differences were not statistically significant ([Fig. 5*G*](#F5){ref-type="fig"}).

Neurons located in the dorsomedial hypothalamus project to brown adipose tissue and are implicated in the acute thermogenic response to cold exposure ([@B27]). Impaired leptin signaling in Nkx2.1-expressing neurons can prevent this response in younger mice ([@B19]). We measured the body temperature of WT and Foxo1KO^Nkx2.1^ mice at room temperature and found a trend toward increased body temperature in Foxo1KO^Nkx2.1^ mice ([Fig. 6*A*](#F6){ref-type="fig"}). These increases may represent thermogenesis, which would not be detected by indirect calorimetry and can account for the decreased fat content of Foxo1KO^Nkx2.1^ mice. However, when we placed mice at 4°C for 4 h to test acute thermogenesis, we failed to see a difference between genotypes ([Fig. 6*A*](#F6){ref-type="fig"}), indicating that the acute sympathetic response to leptin signaling is intact in Foxo1KO^Nkx2.1^ mice. Brown adipose tissue morphology does not appear to be distinct in Foxo1KO^Nkx2.1^ mice ([Fig. 6*B*](#F6){ref-type="fig"}).

![Brown adipose tissue and liver analysis. *A*: Rectal body temperature measured at room temperature and following 4 h of cold exposure at 4°C (*n* = 8). Results are shown as means ± SEM. *B*: H-E staining of brown adipose tissue at room temperature. We show a representative image. *C*: H-E staining of liver from WT and Foxo1KO^Nkx2.1^ mice following regular chow or HFD. We show a representative image. TG (*D*) and total cholesterol (*E*) levels of 7-month-old male mice following overnight fasting. Results are shown as means ± SEM. HF, high fat; hr, hour; RD, regular diet; KO, knockout; Temp, temperature.](1572fig6){#F6}

Finally, in the light of elevated plasma TG levels on HFD, we examined hepatic lipid content in WT and Foxo1KO^Nkx2.1^ mice. However, total lipid content was similarly increased by HFD ([Fig. 6*C*](#F6){ref-type="fig"}), and there were no differences in levels of either hepatic TGs ([Fig. 6*D*](#F6){ref-type="fig"}) or total cholesterol in 10-month-old mice on regular chow ([Fig. 6*E*](#F6){ref-type="fig"}). Glucose tolerance was normal in Foxo1KO^Nkx2.1^ mice on regular chow ([Supplementary Fig. 7](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0651/-/DC1)).

Discussion {#s19}
==========

We generated Foxo1KO^Nkx2.1^ mice with ablation of FoxO1 in hypothalamic Nkx2.1 neurons. These mice are leaner and smaller than WT mice at a young age, but the lean phenotype normalizes with age. There are modest differences in food intake in female knockouts, while EE is similar between the two groups. Given that FoxO1 is a downstream effector of both insulin and leptin signaling, we expected that Foxo1KO^Nkx2.1^ mice would be a model of constitutively active, or at least sensitized, insulin and leptin signaling in hypothalamic neurons. In rats, decreasing hypothalamic insulin receptors results in increased food intake, obesity, and anxiety-like behavior ([@B28],[@B29]). A localized knockdown of insulin receptors or insulin signaling in the VMH does not affect body weight but increases glucagon secretion and results in insulin resistance ([@B30],[@B31]). Although overall hypothalamic insulin receptor signaling inhibits HGP ([@B32]), genetic manipulations of selected hypothalamic neurons reveal opposing actions of insulin in AgRP neurons, where insulin signaling decreases HGP ([@B33]), versus POMC neurons, where insulin appears to increase HGP ([@B7]). In addition to HGP, insulin action in POMC neurons increases POMC neuron numbers in a FoxO1-dependent manner ([@B25]). The cell type--specific nature of insulin signaling among arcuate nucleus neurons may explain the phenotype of Foxo1KO^Nkx2.1^ mice, where glucose levels and hepatic fat content appear to be normal.

Using targeted inactivation of FoxO1 in AgRP and POMC neurons, we have found FoxO1 to be important in the regulation of body weight and food intake ([@B15],[@B16]). While the Nkx2.1-Cre mouse used in these studies does target these types of neurons, the overlap is not complete and is expected to leave FoxO1 intact in ∼15% of adult POMC neurons and up to 45% of Npy neurons ([@B21])---an expectation that is consistent with our finding of ∼24% residual *Foxo1* mRNA within the hypothalamus ([Supplementary Fig. 2*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0651/-/DC1)). Those neurons unaffiliated with the Nkx2.1 lineage may compensate for the decreased FoxO1 in other neurons and result in a mild phenotype. In addition, these data raise the possibility that the phenotype of FoxO1 knockouts driven by AgRP-Cre and POMC-Cre is in fact due not to the arcuate nucleus but to other subpopulations of such neurons in the paraventricular nucleus or brain stem ([@B34]). Alternatively, the activation of Nkx2.1-Cre may selectively reduce a pool of FoxO1 that is regulated by acetylation, not phosphorylation. Mice expressing constitutively acetylated FoxO1 (KR mice) exhibit an increased body weight and fat mass ([@B35]); therefore, the opposite body composition profile of the Foxo1KO^Nkx2.1^ mice may be due in part to deletion of the pool of FoxO1 that undergoes acetylation within neurons of Nkx2.1 lineage.

The compensation in the overall bioenergetics profile of Foxo1KO^Nkx2.1^ mice does not appear to affect body length. Interestingly, Kim et al. ([@B17]) found downregulation of a cluster of IGF-I--related genes when FoxO1 is deleted from the VMH, raising the possibility that Foxo1KO^Nkx2.1^ mice have decreased IGF-I signaling, resulting in decreased length. We also hypothesized that another signaling pathway located within AgRP/Npy neurons, that of ghrelin through the growth hormone secretegogue receptor 1a, might be altered in the Foxo1KO^Nkx2.1^ mice and affect body length ([@B26]). However, we did not find differences in ghrelin receptor transcript or protein level in Foxo1KO^Nkx2.1^ mice (data not shown), and no compensatory changes in activated ghrelin levels in the serum were present.

The differences in male versus female fat composition may be due to differences in innervation of adipose tissue depots. Sexual dimorphism exists in the innervations of abdominal and subcutaneous fat depots from the brain, including leptin-expressing and insulin receptor--expressing neurons ([@B36]). These connections may also contribute to the sexual dimorphism seen in body weight and food intake in mice lacking neuronal insulin receptors ([@B4]) or mice lacking Foxo1 in POMC neurons ([@B16]). Such dimorphism may reveal a need for sex-specific or individualized treatment when targeting the brain for weight reduction.

Decreases in AgRP and Npy are not sufficient alone to manifest body weight dysregulation when altered at an early age, but later deletion of AgRP/Npy in adults has powerful effects on food intake ([@B37]). This phenomenon suggests developmental compensation or redundant mechanisms existing within the neonatal brain that ensure a behavioral desire to eat and thrive. Even removal of both AgRP and NPY can be performed with little body weight or food intake phenotype results, though loss of both genes results in disruption of ghrelin signaling ([@B38],[@B39]). As we could not identify changes in ghrelin receptor expression within the hypothalamus or circulating active ghrelin, the decrease in AgRP and Npy observed in the Foxo1KO^Nkx2.1^ mice is not sufficient to elicit this disruption. In future studies, it will be of interest to explore this possibility by inducing a FoxO1 knockout in adult animals by way of inducible Cre-mediated recombination.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0651/-/DC1>.
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